843666-34-2

Usage

Uses

Used in Bioconjugation Applications:
Octadecanoic acid, 18-[(2,5-dioxo-1-pyrrolidinyl)oxy]-18-oxo-, 1,1-dimethylethyl ester is used as a bioconjugation agent for the specific and efficient attachment of biomolecules, such as proteins or other amine-containing compounds, to various surfaces or supports. The NHS ester moiety allows for the formation of stable covalent bonds with primary amines, enabling the creation of functional bioconjugates for a wide range of applications.
Used in Surface Modification:
In the field of material science, Octadecanoic acid, 18-[(2,5-dioxo-1-pyrrolidinyl)oxy]-18-oxo-, 1,1-dimethylethyl ester can be used for surface modification. Octadecanoic acid, 18-[(2,5-dioxo-1-pyrrolidinyl)oxy]-18-oxo-,
1,1-dimethylethyl ester can react with aminosilane-coated surfaces to form covalent bonds, allowing for the attachment of various functional groups or biomolecules onto the surface. This can be useful for creating surfaces with specific properties, such as improved biocompatibility, enhanced catalytic activity, or targeted binding capabilities.
Used in Drug Delivery Systems:
Octadecanoic acid, 18-[(2,5-dioxo-1-pyrrolidinyl)oxy]-18-oxo-, 1,1-dimethylethyl ester may also find applications in drug delivery systems. The ability to form covalent bonds with primary amines can be utilized to attach drug molecules or other therapeutic agents to various carriers, such as nanoparticles or liposomes. This can improve the stability, solubility, and targeted delivery of drugs, potentially enhancing their therapeutic efficacy and reducing side effects.
Used in Chemical Synthesis:
In the field of organic chemistry, Octadecanoic acid, 18-[(2,5-dioxo-1-pyrrolidinyl)oxy]-18-oxo-, 1,1-dimethylethyl ester can serve as a valuable intermediate or building block in the synthesis of more complex molecules. The presence of the ester group, pyrrolidine ring, and octadecanoic acid chain provides opportunities for further functionalization and modification, making it a versatile component in the development of new chemical entities with potential applications in various industries.

Upstream product

• 7681-38-1 sodium hydrogen sulfate 
• 843666-40-0 1,18-octadecanedioic acid mono-tert-butyl ester 
• 105832-38-0 O-(N-succinimidyl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 
• 74124-79-1 di(succinimido) carbonate 
• 45270-18-6 1,18-octadecanedioyl dichloride 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 871-70-5 octadecanedioic acid 

Downstream Products

• 1118767-15-9 17-(4-(S)-1-tert-butoxycarbonyl-3-{2-[2-({2-[2-(2,5-dioxopyrrolidin-1-yloxycarbonylmethoxy)ethoxy]ethylcarbamoyl}methoxy)ethoxy]ethylcarbamoyl}propylcarbamoyl)heptadecanoic acid tert-butyl ester 

Relevant academic research and scientific papers

Late-stage lipidation of fully elaborated tryptophan-containing peptides for improved pharmacokinetics

The late-stage modification of native peptides to alter and/or enhance their properties and functions is attractive but formidably challenging. Peptide lipidation is one of the effective strategies to overcome short half-life and rapid clearance. Herein, we report a late-stage installation of a fatty acid lipid onto fully elaborated peptides, using glucagon as an example, through regio- and chemoselective functionalization of tryptophan with high potency and remarkable in vivo half-life extension.

METHODS OF MAKING INCRETIN ANALOGS

Intermediate compounds are disclosed for making incretin analogs, or pharmaceutically acceptable salts thereof. In addition, methods are disclosed for making incretin analogs by coupling from two to four of the intermediate compounds herein via hybrid liquid solid phase synthesis or native chemical ligation.

Engineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320

Recently, the first basal oral insulin (OI338) was shown to provide similar treatment outcomes to insulin glargine in a phase 2a clinical trial. Here, we report the engineering of a novel class of basal oral insulin analogues of which OI338, 10, in this publication, was successfully tested in the phase 2a clinical trial. We found that the introduction of two insulin substitutions, A14E and B25H, was needed to provide increased stability toward proteolysis. Ultralong pharmacokinetic profiles were obtained by attaching an albumin-binding side chain derived from octadecanedioic (C18) or icosanedioic acid (C20) to the lysine in position B29. Crucial for obtaining the ultralong PK profile was also a significant reduction of insulin receptor affinity. Oral bioavailability in dogs indicated that C18-based analogues were superior to C20-based analogues. These studies led to the identification of the two clinical candidates OI338 and OI320 (10 and 24, respectively).

AN IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE SIDE CHAIN

The present invention relates to an improved process for the preparation of a compound of Formula (1), The invention also provides improved processes for the preparation of intermediates used in the synthesis of Formula (1). The compound of Formula (1) is used in the synthesis of Semaglutide.

A process for preparing a fatty acid derivative method and its application (by machine translation)

The invention discloses a method for preparing a fatty acid derivative method and its application. The first method is the long-chain fatty acid and thionyl chloride reaction, to obtain the acyl chloride; acyl chloride of preparing butanol reaction, then remove chlorine group, and get long-chain fatty acid uncle ding zhi; then and N - hydroxysuccinimide reaction, long-chain fatty acid succinimide and high yield butylacrylate; then with the L - glutamic acid - 1 - tert-butyl reaction, to obtain tert-butyl long-chain fatty acyl - L - Glu - OtBu; with the N - hydroxysuccinimide reaction, to obtain tert-butyl long-chain fatty acyl - L - Glu (OSu)- OtBu; finally [...] butyl long-chain fatty acyl - L - Glu (OSu)- OtBu tert-butyl in removing, and get long-chain fatty acid derivatives. The method routes the operation is simple, quality is controllable, is suitable for industrial production, and low cost, simple purification at the same time, suitable for use in the preparation of high purity insulin analogs. (by machine translation)

EXENATIDE MODIFIER AND USE THEREOF

Disclosed are an exenatide modifier for connecting the exenatide to a fatty chain with a carboxy in the terminus thereof by means of a hydrophilic connecting arm, and a use thereof in preparing drugs serving as a GLP-1 receptor agonist; a use in preparing drugs for preventing and/or treating diseases and/or symptoms associated with a low GLP-1 receptor activity; a use in preparing drugs for diseases and/or symptoms associated with glycometabolism; a use in preparing drugs for diabetes; a use in preparing drugs for fatty liver disease, and a use in preparing drugs for losing weight.

MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF

The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Protease stabilized acylated insulin analogues

Novel acylated insulin analoges exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analoges contain B25H and A14E or A14H.

MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS

The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Modification of Factor VIII

A Factor VIII derivative of formula (I): wherein: B represents C2 to C10 alkylene; m represents 0 or an integer from 1 to 19, n represents an integer from 1 to 20, and the sum of m and n is from 1 to 20; P represents a mono or polyradical of Factor VIII obtained by removing m+n carbamoyl groups from the side chains of glutamine residues in Factor VIII; and M represents a moiety (M1) that increases the plasma half-life of the Factor VIII derivative or a reporter moiety (M2); or a pharmaceutically acceptable salt thereof.